Medpace Holdings Priced, Nasdaq: MEDP

Global full-service CRO focused on small and mid-sized biopharmaceuticals.

Industry: Health Care

Latest Trade: $29.09 0.00 (0.0%)

First Day Return: +20.8%

Return from IPO: +26.5%

Industry: Health Care

We are one of the world’s leading clinical contract research organizations by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers. Accordingly, we believe we are well positioned to continue to expand our market share and sustain margins in the growing $23 billion overall Phase I-IV CRO market.
more less
IPO News for Medpace Holdings
more
IPO Data
IPO File Date 06/24/2016
Offer Price $23.00
Price Range $20.00 - $23.00
Offer Shares (mm) 7.0
Deal Size ($mm) $161
IPO Data
IPO Date 08/10/2016
Offer Price $23.00
Price Range $20.00 - $23.00
Offer Shares (mm) 7.0
Deal Size ($mm) $161
Underwriters
more
Company Data
Headquarters Cincinnati, OH
Founded 1992
Employees 2,300
Website www.medpace.com